FDA (US): Approved (2007, Somatuline Depot) for acromegaly; expanded to gastroenteropancreatic neuroendocrine tumors (2014) and carcinoid syndrome (2017).
EMA (EU): No centralized EMA authorization; authorized nationally in Spain and other EU countries (Somatuline Autogel) for acromegaly, neuroendocrine tumors, and carcinoid syndrome.
120 mg by deep subcutaneous injection every 28 days in neuroendocrine tumors; in acromegaly, 60–120 mg every 4 weeks depending on response (FDA label).
It may reduce cyclosporine absorption; insulin or antidiabetic drugs may need adjusting; caution with drugs that slow the heart rate (beta-blockers).
202 patients with metastatic tumors, 96 weeks. Lanreotide 120 mg every 28 days halved the risk of progression (HR 0.47): at 2 years, 65% vs 33% with placebo remained progression-free. Overall survival did not change.
View the study (RCT) →It binds to somatostatin receptors (mainly types 2 and 5) and slows the release of growth hormone, IGF-1, and the hormones produced by neuroendocrine tumors. It also slows the growth of these tumors.
In people
Information, not medical advice. Prescription or unapproved peptides should only be used under medical supervision.